IL2 and neoplasm: According to Sun et al.'s study, rAd-IL-2 exhibits a significant induced anti-tumor immune response by recruiting CD4+ and CD8+T cells, increasing the interferon-γ release, and stimulating cytotoxic T lymphocyte responses in the HCC tumor model (53).